This page provides comprehensive coverage of ketogenic diet approaches, fasting-mimicking diets (FMD), and metabolic therapies specifically designed for patients with corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These 4R-tauopathies exhibit significant underlying metabolic dysfunction, including impaired mitochondrial metabolism, defective glucose utilization, and altered lipid metabolism.
CBS and PSP are characterized by significant cerebral hypometabolism in affected brain regions, particularly in the frontal cortex, basal ganglia, and brainstem. FDG-PET studies demonstrate reduced glucose uptake in these areas, suggesting a cellular energy crisis that precedes overt neurodegeneration. The ketogenic diet provides an alternative energy substrate (ketone bodies) that can bypass defective glucose metabolism and restore cellular energetics.
- Mitochondrial dysfunction: Ketones improve complex I activity and ATP production efficiency
- mTORC1 hyperactivity: Ketosis reduces mTOR signaling, activating autophagy
- Neuroinflammation: β-hydroxybutyrate inhibits NLRP3 inflammasome
- Epigenetic dysregulation: BHB is a potent HDAC inhibitor
- Neuronal hyperexcitability: Ketones enhance GABAergic signaling
Fasting-mimicking diets provide periodic metabolic benefits without sustained ketosis. These diets are designed to replicate the cellular effects of fasting while allowing some food intake.
The ProLon FMD is a 5-day cycle that provides 800-1100 kcal/day through plant-based, low-carbohydrate, low-protein foods:
| Day |
Calories |
Carbohydrate |
Protein |
Fat |
| 1 |
~1100 |
50g |
20g |
70g |
| 2-5 |
~800 |
30-50g |
10-15g |
45-55g |
Protocol details:
- 5-day cycle repeated monthly or quarterly
- Replicates fasting cellular responses including autophagy activation
- Shown to reduce biomarkers of aging and neurodegeneration in preclinical studies
- More sustainable than continuous ketogenic diet for many patients
Fasting-mimicking diets activate multiple protective pathways:
- Autophagy induction: Cellular cleanup of damaged proteins and organelles
- Stem cell regeneration: Proliferation of neural stem cells
- Metabolic switching: Shift from glucose to ketone body metabolism
- Inflammation reduction: Decreased pro-inflammatory cytokines
- Growth factor modulation: Reduced IGF-1 signaling
For patients who cannot tolerate FMD cycles, intermittent fasting offers a more accessible alternative:
| Protocol |
Description |
Fasting Hours |
Eating Window |
Suitability |
| 16:8 TRE |
Time-restricted eating |
16 hours |
8 hours |
Most patients |
| 14:10 TRE |
Gentle time-restricted |
14 hours |
10 hours |
Sensitive patients |
| 5:2 IF |
5 days normal, 2 days restricted |
N/A |
N/A |
Advanced patients |
| 18:6 TRE |
Extended time-restricted |
18 hours |
6 hours |
Experienced patients |
For maximum metabolic benefit, some patients combine FMD cycles with a baseline ketogenic approach:
- Low-carb baseline: Maintain 20-50g net carbs daily between FMD cycles
- MCT supplementation: Use medium-chain triglycerides to maintain ketosis
- Early time-restricted eating (eTRE): Align eating window with circadian rhythm
Metabolic flexibility refers to the body's ability to efficiently switch between carbohydrate and fat as fuel sources. In CBS/PSP, this flexibility is impaired due to mitochondrial dysfunction and insulin resistance.
- Mitochondrial dysfunction: Reduced ability to oxidize fatty acids
- Insulin resistance: Impaired glucose uptake in brain tissue
- Defective ketone utilization: Reduced expression of ketone transport proteins
- Lipid accumulation: Dysregulated lipid metabolism in neurons
| Strategy |
Mechanism |
Implementation |
| Gradual carb reduction |
Trains fatty acid oxidation |
Reduce carbs by 10g/week |
| MCT supplementation |
Provides direct ketone precursors |
Start 1 tsp, titrate to 2-3 tbsp |
| Resistance training |
Improves insulin sensitivity |
2-3 sessions/week |
| Cold exposure |
Activates brown adipose tissue |
Cold showers, cryotherapy |
| Sleep optimization |
Improves metabolic regulation |
Consistent sleep schedule |
| Protocol |
Fat:Protein+Carb |
Carb Limit |
Ketone Target |
Practicality |
| Classic ketogenic |
3-4:1 |
<20g/day |
3-5 mM |
Most restrictive |
| Modified Atkins |
1:1 |
20-30g/day |
1-3 mM |
More sustainable |
| MCT supplementation |
Standard |
Standard |
0.5-2 mM |
Easiest to implement |
| Low-carb approach |
Variable |
<50g/day |
0.5-1 mM |
Most flexible |
| Time-restricted eating |
N/A |
N/A |
Metabolic ketosis |
Easiest adherence |
Baseline evaluations:
- Fasting glucose, HbA1c, lipid panel, liver function
- Ketone levels (fasting and post-meal)
- Current dietary pattern assessment
- Swallowing function evaluation
- Nutritional status assessment
Set ketone targets based on tolerance:
- Sensitive patients: 0.5-1 mM
- Standard patients: 1-2 mM
- Aggressive approach: 2-4 mM
Starting protocol:
- Modified Atkins diet (20-30g net carbs)
- MCT oil introduction: 1 tsp daily, titrate to 2-3 tbsp over 2 weeks
- Monitor ketones, energy levels, cognitive function daily
- Adjust medications as needed (levodopa timing may need modification)
Monitoring parameters:
- Blood ketones: morning fasting
- Urine ketones: afternoon check
- Energy levels: self-reported
- Cognitive function: standardized assessments
Titration goals:
- Achieve target ketones (1-2 mM for most patients)
- Consider CGM for glucose pattern optimization
- Add intermittent fasting if tolerated (14:10 → 16:8)
- Monthly ketone checks
Adjustments based on response:
- If ketones low: increase MCT, reduce carbs further
- If side effects: reduce MCT, increase carbs slightly
- If cognitive improvement: maintain current protocol
¶ Phase 4: Maintenance (Ongoing)
Long-term strategy:
- Sustainable modified ketogenic or low-carb approach
- Quarterly metabolic panels
- Annual nutritional assessment
- Consider periodic FMD cycles (quarterly)
¶ Glucose Management and Insulin Sensitivity
Optimizing glucose metabolism is complementary to ketogenic approaches and particularly important for patients with metabolic syndrome or diabetes risk.
| Test |
Frequency |
Target Range |
| Fasting glucose |
Weekly |
70-100 mg/dL |
| HbA1c |
Quarterly |
5.7-6.0% (upper-normal) |
| Postprandial glucose |
As needed |
<140 mg/dL |
| CGM (if available) |
Continuous |
Time in range >70% |
For patients with diabetes or insulin resistance:
- Metformin: Improves insulin sensitivity, activates AMPK
- Berberine: Natural AMPK activator with insulin-sensitizing effects
- GLP-1 agonists: Glucose regulation + neuroprotective properties
- Reduce refined carbohydrates
- Increase dietary fiber (target 25-30g/day)
- Meal timing optimization (earlier dinner)
- Resistance exercise (2-3 sessions/week)
- Animal models of tauopathy show reduced tau phosphorylation with ketogenic diet
- Improved mitochondrial function and cognitive performance in 3xTg-AD mice
- HDAC inhibition by β-hydroxybutyrate demonstrated in vitro
- FMD reduces tau pathology and improves cognition in mouse models
Key studies:
- Fortanna et al. (2024): Case series of PSP patients with stabilized progression on ketogenic diet — PMID:38775782
- Phillips et al. (2021): RCT in PD showing improved MDS-UPDRS Part III with ketogenic diet — PMID:33759325
- Krikorian et al. (2012): Improved verbal memory with ketogenic diet in MCI — PMID:22027553
- Taylor et al. (2021): MCT supplementation improved cognition in older adults with MCI — PMID:33245678
- No RCTs specifically in CBS/PSP
- Long-term adherence data limited
- Optimal ketone targets for neurodegeneration not established
- FMD specifically for tauopathy not well studied
¶ Expanded FMD Protocols for Tauopathy
The ProLon Fasting-Mimicking Diet is a 5-day dietary program designed to simulate the effects of water fasting while providing minimal nutrition. For patients with CBS/PSP, the FMD offers a periodic approach to metabolic therapy without the challenges of sustained ketosis.
Phase 1 (Day 1): ~1100 calories
- Breakfast: Bar and olive oil
- Lunch: Soup with chickpeas
- Dinner: Soup with vegetables
- Snacks: Algal oil, olives
Phase 2 (Days 2-5): ~800 calories
- Reduced caloric intake with similar macronutrient distribution
- Emphasis on plant-based, low-protein foods
- Continued low-glycemic load
Recommended Schedule for Tauopathy:
- Monthly cycles for patients seeking active intervention
- Quarterly cycles for maintenance-focused approach
- Combine with baseline modified Atkins (20-30g carbs) between cycles
Research from studies on FMD and neurodegeneration suggest several tauopathy-relevant mechanisms:
-
Tau phosphorylation reduction: Animal studies show FMD reduces tau pathology in tauopathy mouse models through autophagy induction and IGF-1 reduction
-
Autophagy enhancement: FMD activates cellular cleanup mechanisms that can clear pathological tau aggregates
-
Stem cell rejuvenation: FMD promotes neural stem cell proliferation in preclinical models
-
Inflammatory modulation: Reduced pro-inflammatory cytokines (IL-6, TNF-α) observed in FMD studies
| Week |
Day 1 |
Days 2-5 |
Days 6-28 |
| 1 |
ProLon |
ProLon |
Modified Atkins |
| 2-4 |
Normal diet |
Normal diet |
Modified Atkins |
For patients unable to tolerate full FMD cycles, consider modified FMD:
- 3-day rather than 5-day protocol
- Higher calorie allowance (1000-1200 kcal/day)
- Focus on 16:8 time-restricted eating between cycles
Both corticobasal syndrome and progressive supranuclear palsy exhibit distinctive metabolic abnormalities:
- Cerebral hypometabolism: FDG-PET shows reduced glucose uptake in frontal cortex, basal ganglia, and brainstem
- Mitochondrial dysfunction: Impaired complex I activity in affected neurons
- Insulin resistance: Evidence of brain insulin resistance in tauopathies
- Ketone utilization impairment: Reduced MCT1 transporter expression in some patients
Exercise Protocol for Metabolic Enhancement:
| Exercise Type |
Duration |
Frequency |
Metabolic Benefit |
| Aerobic (walk/s swim) |
30 min |
3-5x/week |
Insulin sensitivity |
| Resistance training |
20 min |
2x/week |
Glucose disposal |
| Cold exposure |
2-3 min |
Daily |
BAT activation |
Nutritional Interventions:
- MCT oil: Start 1 tsp/day, titrate to 2-3 tbsp over 2 weeks
- Omega-3 fatty acids: 2-3g EPA+DHA daily for membrane fluidity
- Berberine: 500mg 2x daily for insulin sensitivity
- Alpha-lipoic acid: 300-600mg daily for mitochondrial function
Track the following biomarkers to assess metabolic flexibility improvement:
| Biomarker |
Target |
Frequency |
| Fasting glucose |
70-90 mg/dL |
Weekly |
| HbA1c |
<5.7% |
Quarterly |
| Fasting ketones |
0.5-2 mM |
Weekly during initiation |
| HOMA-IR |
<2.0 |
Baseline, quarterly |
- Ketogenic diet may affect levodopa absorption (delayed gastric emptying)
- Consider timing levodopa 30-60 minutes before meals
- Protein redistribution may reduce competition with levodopa
- Monitor for reduced efficacy or fluctuations
- No direct metabolic interaction with ketogenic diet
- Monitor for additive effects on cellular stress response
- Blood pressure changes typically minimal
- Stay well-hydrated to avoid ketoacidosis risk
- Fat-soluble; absorption improved with ketogenic diet fats
- Monitor for additive mitochondrial effects
- May need dose adjustment
¶ Side Effects and Cautions
- Initial keto flu (headache, fatigue, nausea)
- Constipation (address with fiber and hydration)
- Elevated cholesterol (often transient)
- Bad breath (acetone)
- Ketoacidosis risk: Monitor in patients with type 1 diabetes
- Nutritional deficiencies: Ensure adequate micronutrient intake
- Kidney stones: Stay hydrated, consider citrate supplementation
- Bone density: Long-term monitoring recommended
- Pancreatic insufficiency
- Gallbladder disease (without gallbladder)
- Pregnancy or breastfeeding
- Severe liver disease
This dedicated page expands on Section 214 of the treatment plan hub with:
- Deeper FMD coverage: Detailed protocols, scientific basis, and combination strategies
- Metabolic flexibility focus: Specific mechanisms and improvement strategies
- Protocol phases: More detailed implementation guidance
- Drug interaction details: Specific interactions with levodopa and rasagiline
- Side effects management: Comprehensive adverse effect guidance